Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

OBJECTIVES: To evaluate treatment with the peptide-based agent, Lupuzor, in a double-blind, randomised, placebo-controlled study of patients with systemic lupus erythematosus. METHODS: Patients who met ≥4 of the American College of Rheumatology criteria, had a score of ≥6 on the Systemic Lupus Eryth...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmer, Robert, Scherbarth, Hugo R, Rillo, Oscar Luis, Gomez-Reino, Juan Jesus, Muller, Sylviane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812851/
https://www.ncbi.nlm.nih.gov/pubmed/23172751
http://dx.doi.org/10.1136/annrheumdis-2012-202460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812851/
https://www.ncbi.nlm.nih.gov/pubmed/23172751
http://dx.doi.org/10.1136/annrheumdis-2012-202460

Ejemplares similares